Smart drugs: Tyrosine kinase inhibitors in cancer therapy

Cancer Cell

Volumn 1, Issue 2, 2002, Pages 117-123

  Shawver, Laura K ^a   Slamon, Dennis ^b   Ullrich, Axel ^c  

^a SUGEN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; TRASTUZUMAB; VANDETANIB; VATALANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR;

BREAST CARCINOMA; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; GENE OVEREXPRESSION; GENE TARGETING; GENOMICS; HUMAN; MEDICAL PRACTICE; MEDICAL RESEARCH; MOLECULAR DYNAMICS; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; ENZYMOLOGY; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 0036490442     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00039-9     Document Type: Review

References (61)

1. Albanell, J., Rojo, F., and Baselga, J. (2001). Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin. Oncol. 28, 56-66.
2. Allan, N.C., Richards, S.M., and Shepherd, P.C. (1995). UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345, 1392-1397.
3. Baselga, J., Herbst, R., Lorusso, P., and Rischin, D. (2000). Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proc. Am. Soc. Clin. Oncol. 19, 177a.
4. Blanke, C.D., von Mehren, M., Joensuu, H., Roberts, P.J., and Eisenberg, B. (2001). Evaluation of the Safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117). Proc. Am. Soc. Clin. Oncol. 20, 1a.
5. Borg, J.P., Marchetto, S., Le Bivic, A., Ollendorff, V., Jaulin-Bastard, F., Saito, H., Fournier, E., Adelaide, J., Margolis, B., and Birnbaum, D. (2000). ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat. Cell Biol. 2, 407-414.
6. Browder, T., Butterfield, C.E., Kraling, B.M., Shi, B., Marshall, B., O'Reilly, M.S., and Folkman, J. (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886.
7. Budillon, A., Di Gennaro, E., Barbarino, M., and Bruzzese, F. (2000). ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, upregulates P27KIP1 inducing G1 arrest and enhancing the antitumor effect of interferon a. Proc. Am. Assoc. Cancer. Res. 41, 773.
8. Carter, P., Presta, L., German, C.M., Ridgway, J.B., Henner, D., Wong, W.L., Rowland, A.M., Kotts, C., Carver, M.E., and Shepard, H.M. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89, 4285-4289.
9. Chazin, V.R., Kaleko, M., Miller, A.D., and Slamon, D.J. (1992). Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7, 1859-1866.
10. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S., Bianco, A.R., and Tortora, G. (2000). Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053-2063.
11. Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., Wolter, J.M., Paton, V., Shak, S., Lieberman, G., and Slamon, D.J. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648.
12. Cohen, P.S., Chan, J.P., Lipkunskaya, M., Biedler, J.L., and Seeger, R.C. (1994). Expression of stem cell factor and c-kit in human neuroblastoma. Blood 84, 3465-3472.
13. Daley, G.Q., Van Etten, R.A., and Baltimore, D. (1990). Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830.
14. de Klein, A., van Kessel, A.G., Grosveld, G., Bartram, C.R., Hagemeijer, A., Bootsma, D., Spurr, N.K., Heisterkamp, N., Groffen, J., and Stephenson, J.R. (1982). A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765-767.
15. Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., and Waterfield, M.D. (1984). Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307, 521-527.
16. Druker, B.J. (2002). Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31-36.
17. Ellis, L.M., Liu, W., Ahmad, S.A., Fan, F., Jung, Y.D., Shaheen, R.M., and Reinmuth, N. (2001). Overview of angiogenesis: Biologic implications for antiangiogenic therapy. Semin. Oncol. 28, 94-104.
18. Fendly, B.M., Winget, M., Hudziak, R., Lipari, M.T., Napier, M.A., and Ullrich, A. (1990). Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor of HER2/neu gene product. Cancer Res. 50, 1550-1558.
19. Ferry, D., Hammond, L., Ranson, M., and Kris, M. (2000). Intermittent Oral Zd1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows evidence of good tolerability and activity: final results from a phase I study. Proc. Am. Soc. Clin. Oncol. 19, 3a.
20. Folkman, J. (1999). Angiogenesis research: from laboratory to clinic. Forum 9, 59-62.
21. Fong, T.A., Shawver, L.K., and Sun, L. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59, 99-106.
22. Fox, S.B., Gasparini, G., and Harris, A.L. (2001). Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anti-cancer drugs. Lancet 2, 278-289.
23. Geng, L., Donnelly, E., McMahon, G., Lin, P.C., Sierra-Rivera, E., Oshinka, H., and Hallahan, D.E. (2001). Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61, 2413-2419.
24. George, D. (2001). Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin. Oncol. 28, 27-33.
25. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., and Sawyers, C.L. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880.
26. Gorski, D.H., Beckett, M.A., Jaskowiak, N.T., Calvin, D.P., Mauceri, H.J., Salloum, R.M., Seetharam, S., Koons, A., Hari, D.M., Kufe, D.W., and Weichselbaum, R.R. (1999). Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374-3378.
27. Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P.K., and Groffen, J. (1990). Acute leukaemia in bcr/abl transgenic mice. Nature 344, 251-253.
28. Hibi, K., Takahashi, T., Sekido, Y., Ueda, R., Hida, T., Ariyoshi, Y., Takagi, H., and Takahashi, T. (1991). Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6, 2291-2296.
29. Hines, S.J., Organ, C., Kornstein, M.J., and Krystal, G.W. (1995). Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ. 6, 769-779.
30. Hochhaus, A., Kreil, S., Corbin, A., La Rosee, P., Lahaye, T., Berger, U., Cross, N.C., Linkesch, W., Druker, B.J., Hehlmann, R., et al. (2001). Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163.
31. Jiang, W., Hiscox, S., Matsumoto, K., and Nakamura, T. (1999). Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit. Rev. Oncol. Hematol. 29, 209-248.
32. Kanakura, Y., Ikeda, H., Kitayama, H., Sugahara, H., and Furitsu, T. (1993). Expression, function and activation of the proto-oncogene c-kit product in human leukemia cells. Leuk. Lymphoma 10, 35-41.
33. Kawamoto, T., Sato, J.D., Le, A., Polikoff, J., Sato, G.H., and Mendelsohn, J. (1983). Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. USA 80, 1337-1341.
34. Kelliher, M.A., McLaughlin, J., Witte, O.N., and Rosenberg, N. (1990). Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87, 6649-6653.
35. Kozin, S.V., Boucher, Y., Hicklin, D.J., Bohlen, P., Jain, R.K., and Suit, H.D. (2001). Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39-44.
36. Liekens, S., De Clercq, E., and Neyts, J. (2001). Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61, 253-270.
37. Longati, P., Comoglio, P.M., and Bardelli, A. (2001). Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. Current Drug Targets 2, 41-55.
38. Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A. (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579.
39. Miller, L.L., Elfring, G.L., Hannah, A.L., and Allred, R. (2001). Efficacy results of a phase I/II study of SU5416 (S)/5-fluorouracil (F)/leucovorin (L) relative to results in random subsets of similar patients (Pts) from a phase III study of irinotecan (C)/F/L or F/L alone in the therapy of previously untreated metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. 20, 144a.
40. Moulder, S.L., Yakes, M., Bianco, R., and Arteage, C. (2001). Small molecule EGF receptor tyrosine kinase inhibitor ZD 1839 (IRESSA) inhibits HER2/Neu (erb-2) overexpressing breast tumor cells. Proc. Am. Soc. Clin. Oncol. 20, 3a.
41. Nicholson, R.I., Gee, J.M., and Harper, M.E. (2001). EGFR and cancer prognosis. Eur. J. Cancer 37 (Suppl 4), S9-15.
42. Ostman, A., and Heldin, C.H. (2001). Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res. 80, 1-38.
43. Padhani, A.R., and Neeman, M. (2001). Challenges for imaging angiogenesis. Br. J. Radiol. 74, 886-890.
44. Pinedo, H.M., and Slamon, J. (2000). Translational research: the role of VEGF in tumor angiogenesis. Oncologist 5, 1-2.
45. Rieske, P., Bartkowiak, J.K., Szadowska, A.M., Olborski, B., Harezga-Bal, B., and Debiec-Rychter, M. (1999). A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas. J. Exp. Clin. Cancer Res. 18, 403-416.
46. Rosen, P.J., Amado, R., Hecht, J.R., and Chang, D. (2000). A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 19, 3a.
47. Rowley, J.D. (1973). Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290-293.
48. Shah, N.P., Nicoll, J.M., Gorre, M.E., Paquette, R.L., and Ford, J. (2001). Resistance to Gleevec: sequence analysis reveals a spectrum of Bcr/ABL kinase domain mutations in both acquired- and de novo-resistance cases of chronic myelogenous leukemia (CML) in myeloid blast crisis. Am. Soc. Hematol. 770a.
49. Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell 103, 211-225.
50. Shawver, L.K. (1999). Tyrosine kinase inhibitors: from the emergence of targets to their clinical development. In American Society of Clinical Oncology 1999 Educational Book, M.C. Perry, ed. (Alexandria, VA: American Society of Clinical Oncology), pp. 29-52.
51. Shepard, H.M., Lewis, G.D., Sarup, J.C., Fendly, B.M., Maneval, D., Mordenti, J., Figari, I., Kotts, C.E., Palladino, M.A., Jr., and Ullrich, A. (1991). Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 11, 117-127.
52. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
53. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792.
54. Strohmeyer, T., Peter, S., Hartmann, M., Munemitsu, S., Ackermann, R., Ullrich, A., and Slamon, D.J. (1991). Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res. 51, 1811-1816.
55. Ullrich, A., Coussens, L., Hayflick, J.S., Dull, T.J., Gray, A., Tam, A.W., Lee, J., Yarden, Y., Libermann, T.A., and Schlessinger, J. (1984). Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418-425.
56. Vajkoczy, P., Menger, M.D., and Vollmar, B. (1999). Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1, 31-41.
57. Van Oosterom, A.T., Judson, I., Verweij, J., Stroobants, S., Donato, D.P., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001). Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358, 1421-1423.
58. van der Vort, V., Taher, T.E., Derksen, P.W., Spaargaren, M., van der Neut, R., and Pals, S.T. (2000). The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv. Cancer Res. 79, 39-90.
59. Varmus, H., and Bishop, J.M. (1986). Biochemical mechanisms of oncogene activity: proteins encoded by oncogenes. Introduction. Cancer Surveys 5, 153-158.
60. Yarden, Y., and Sliwkowski, M.X. (2001). Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2, 127-137.
61. Yu, D. (2001). Mechanisms of ErbB2-mediated paclitaxel resistance and Herceptin-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin. Oncol. 28, 12-17.